Resumen de acción EQS
Equasens Société anonyme ofrece soluciones informáticas sanitarias en Europa.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Recompensas
Análisis de riesgos
No se han detectado riesgos en EQS a partir de nuestros controles de riesgos.
Competidores de Equasens Société anonyme
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | €58.90 |
| 52 Week High | €85.80 |
| 52 Week Low | €46.15 |
| Beta | 0.94 |
| 1 Month Change | 14.81% |
| 3 Month Change | 10.51% |
| 1 Year Change | -17.04% |
| 3 Year Change | -38.26% |
| 5 Year Change | 4.62% |
| Change since IPO | 1,282.63% |
Noticias y actualizaciones recientes
Equasens Société anonyme (EPA:EQS) Is Aiming To Keep Up Its Impressive Returns
Apr 03
At €51.10, Is It Time To Put Equasens Société anonyme (EPA:EQS) On Your Watch List?
Mar 08Some Confidence Is Lacking In Equasens Société anonyme's (EPA:EQS) P/E
Feb 14Recent updates
Equasens Société anonyme (EPA:EQS) Is Aiming To Keep Up Its Impressive Returns
Apr 03At €51.10, Is It Time To Put Equasens Société anonyme (EPA:EQS) On Your Watch List?
Mar 08Some Confidence Is Lacking In Equasens Société anonyme's (EPA:EQS) P/E
Feb 14Estimating The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Jan 27Should You Investigate Equasens Société anonyme (EPA:EQS) At €59.70?
Nov 29These 4 Measures Indicate That Equasens Société anonyme (EPA:EQS) Is Using Debt Safely
Oct 28A Look At The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Sep 27Should You Think About Buying Equasens Société anonyme (EPA:EQS) Now?
Aug 05Equasens Société anonyme (EPA:EQS) Is Increasing Its Dividend To €1.15
Jun 11Equasens Société anonyme's (EPA:EQS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 22Equasens Société anonyme's (EPA:EQS) Shareholders Will Receive A Bigger Dividend Than Last Year
May 08What Does Equasens Société anonyme's (EPA:EQS) Share Price Indicate?
Apr 04Equasens Société anonyme (EPA:EQS) Will Want To Turn Around Its Return Trends
Feb 13Calculating The Intrinsic Value Of Equasens Société anonyme (EPA:EQS)
Jan 26At €71.60, Is Equasens Société anonyme (EPA:EQS) Worth Looking At Closely?
Dec 21Should You Be Adding Equasens Société anonyme (EPA:EQS) To Your Watchlist Today?
Dec 07Here's What's Concerning About Equasens Société anonyme's (EPA:EQS) Returns On Capital
Nov 12Is Equasens Société anonyme (EPA:EQS) Trading At A 26% Discount?
Oct 27Is Equasens Société anonyme (EPA:EQS) Using Too Much Debt?
Oct 12When Should You Buy Equasens Société anonyme (EPA:EQS)?
Sep 09With EPS Growth And More, Equasens Société anonyme (EPA:EQS) Makes An Interesting Case
Aug 24Equasens Société anonyme (EPA:EQS) Might Be Having Difficulty Using Its Capital Effectively
Jul 28Equasens Société anonyme (EPA:EQS) Is Increasing Its Dividend To €1.05
Jun 10Pharmagest Interactive (EPA:PHA) Has Announced That It Will Be Increasing Its Dividend To €1.05
May 27Is Now The Time To Put Pharmagest Interactive (EPA:PHA) On Your Watchlist?
May 22Here's What Pharmagest Interactive's (EPA:PHA) Strong Returns On Capital Mean
Apr 25Are Investors Undervaluing Pharmagest Interactive SA (EPA:PHA) By 28%?
Feb 23Here's Why I Think Pharmagest Interactive (EPA:PHA) Might Deserve Your Attention Today
Feb 09Is Pharmagest Interactive SA (EPA:PHA) Potentially Undervalued?
Jan 25Many Would Be Envious Of Pharmagest Interactive's (EPA:PHA) Excellent Returns On Capital
Jan 06Pharmagest Interactive (EPA:PHA) Could Easily Take On More Debt
Nov 14Is There An Opportunity With Pharmagest Interactive SA's (EPA:PHA) 20% Undervaluation?
Oct 30Is Now The Time To Put Pharmagest Interactive (EPA:PHA) On Your Watchlist?
Sep 28Is Pharmagest Interactive SA (EPA:PHA) Trading At A 20% Discount?
Jul 18Pharmagest Interactive (EPA:PHA) Will Want To Turn Around Its Return Trends
Jun 24Does Pharmagest Interactive (EPA:PHA) Deserve A Spot On Your Watchlist?
Apr 08Pharmagest Interactive SA (EPA:PHA) Is An Attractive Dividend Stock - Here's Why
Mar 24Pharmagest Interactive SA's (EPA:PHA) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 03Our Take On The Returns On Capital At Pharmagest Interactive (EPA:PHA)
Feb 09
Shareholders of Pharmagest Interactive (EPA:PHA) Must Be Delighted With Their 500% Total Return
Jan 12What To Know Before Buying Pharmagest Interactive SA (EPA:PHA) For Its Dividend
Dec 15Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmagest Interactive SA's EPA:PHA) Stock?
Dec 01Rentabilidad de los accionistas
| EQS | FR Healthcare Services | Mercado FR | |
|---|---|---|---|
| 7D | -1.5% | 2.9% | 0.002% |
| 1Y | -17.0% | 1.3% | 3.0% |
Rentabilidad vs. Industria: EQS obtuvo unos resultados inferiores a los del sector French Healthcare Services , que el año pasado arrojó un rendimiento del 0.6%.
Rentabilidad vs. Mercado: EQS obtuvo unos resultados inferiores a los del mercado French, que fue del 4% el año pasado.
Volatilidad de los precios
| EQS volatility | |
|---|---|
| EQS Average Weekly Movement | 5.1% |
| Healthcare Services Industry Average Movement | 6.5% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.3% |
| 10% least volatile stocks in FR Market | 2.3% |
Precio estable de las acciones: EQS no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de EQS (5%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1996 | 1,200 | Denis Supplisson | equasens.com |
Equasens Société anonyme proporciona soluciones informáticas sanitarias en Europa. Ofrece id. PATIENT, un software empresarial; id.
Resumen de fundamentos de Equasens Société anonyme
| Estadísticas fundamentales de EQS | |
|---|---|
| Capitalización bursátil | €891.47m |
| Beneficios(TTM) | €48.50m |
| Ingresos (TTM) | €223.12m |
18.3x
Ratio precio-beneficio (PE)4.0x
Ratio precio-ventas (PS)¿Está EQS sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de EQS | |
|---|---|
| Ingresos | €223.12m |
| Coste de los ingresos | €150.32m |
| Beneficio bruto | €72.81m |
| Otros gastos | €24.31m |
| Beneficios | €48.50m |
Últimos beneficios comunicados
Jun 30, 2023
Próxima fecha de beneficios
Sep 27, 2024
| Beneficios por acción (BPA) | 3.23 |
| Margen bruto | 32.63% |
| Margen de beneficio neto | 21.74% |
| Ratio deuda/patrimonio | 28.9% |
¿Cómo se ha desempeñado EQS a largo plazo?
Ver rendimiento histórico y comparativa